TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03019991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
Study: NCT01014247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Single dose of 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching tablet
Study: NCT03186144

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blodd punction for genetic analysis
Study: NCT03153553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
Study: NCT01809860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral
Study: NCT03225690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Prevention of remifentanil induced hyperalgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Prevention of remifentanil induced hyperalgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Serum physiologic
Description: For placebo, serum physiologic will use
Study: NCT03952091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ202, Lenalidomide and Dexamethasone
Description: One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide and Dexamethasone
Description: Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
Study: NCT04900675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright light intervention
Description: Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reddish placebo light
Description: Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
Study: NCT02954198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: goal trough level 5-12ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: goal trough level 5-12ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: goal dose 5mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: goal dose 5mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: goal dose 1g BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: goal trough level 3-8ng/mL
Study: NCT05303389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation of 2,3 or 4 column pilon fracture of the tibia
Description: anterior to posterior screws in classic arm and posterolateral approach in new arm group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation of 2,3 or 4 column pilon fracture of the tibia
Description: anterior to posterior screws in classic arm and posterolateral approach in new arm group
Study: NCT02119442

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcather Valve Implantation
Description: Transcather Valve Implantation
Study: NCT01346072

Intervention type: DRUG
Group type: OTHER
Intervention: tolvaptan
Description: oral, 30 mg, single dose, one time administration
Study: NCT00162916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: 20mg or 40mg, once daily, for 40 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch
Study: NCT03599102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOVED Intervention
Study: NCT03432442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin once every 24 hours for three administrations
Study: NCT01904110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate/Cholecalciferol combination(montly)
Description: once a month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate/Cholecalciferol combination(montly)
Description: once a month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate/Cholecalciferol combination(weekly)
Description: once a week
Study: NCT04065243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding diet
Description: Two weeks of overfeeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric diet
Description: Two weeks of isocaloric weight maintenance
Study: NCT00713843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Utrecht
Description: Manual Therapy (6 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical Therapy (six weeks).
Study: NCT01114009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver
Description: Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
Study: NCT03432442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin once every 24 hours for three administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin once every 24 hours for three administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin once every 24 hours for three administrations
Study: NCT01114009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung protective strategy group
Description: Lung protective strategy group received Lung protective strategy without recruitment maneuver

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective strategy group
Description: Lung protective strategy group received Lung protective strategy without recruitment maneuver
Study: NCT02812589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) in Breast MRI
Study: NCT04420728

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early auto-mode
Description: Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed auto mode
Description: Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
Study: NCT02956538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo(for thalidomide)
Description: sugar pill manufactured to mimic thalidomide 100mg tablet
Study: NCT00712257

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface
Description: treatment for superficial femoral artery instent re-stenosis
Study: NCT01617239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)
Study: NCT02620683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See above

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See above
Study: NCT05915273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Aided Design/ Computer Aided Manufacturing Retainers
Description: Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH \& Co., Ispringen, Germany)- were used for the CAD/CAM group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lab-based Retainers
Description: The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chairside Retainers
Description: The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
Study: NCT03771963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TDV)
Description: TDV SC injection.
Study: NCT01116037

Intervention type: DEVICE
Group type: OTHER
Intervention: ATS 3f Aortic Bioprosthesis
Description: Equine Pericardial Bioprosthesis for replacement of diseased valve
Study: NCT03461198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Silk
Description: Restylane® Silk to a defined area of mid to low cheeks
Study: NCT02708550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Organizational Intervention
Study: NCT02185417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone (CTD)
Description: Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
Study: NCT01158560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gargling
Description: gargling with tap water, twice daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gargling
Description: gargling with tap water, twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo for active vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo for active vitamin D
Study: NCT01005069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS-32
Description: DLBS-32 50 mg once daily and lifestyle modification
Study: NCT04043429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vision Restoration Training (VRT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vision Exploration Training (VET)
Study: NCT02068911

Intervention type: DEVICE
Intervention: Monitoring of ETCO2 and PTCO2
Description: Concomitant monitoring of ETCO2 and PTCO2
Study: NCT02044757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSB withdrawal
Description: During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
Study: NCT03327389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
Study: NCT00660296

Intervention type: OTHER
Group type: OTHER
Intervention: Air insufflation use in colonoscopy
Description: Air insufflation for colonic distension

Intervention type: OTHER
Group type: OTHER
Intervention: CO2 use in colonoscopy
Description: Co2 insufflation for colonic distension
Study: NCT02862145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX34
Description: Treatment of melanoma with pharmacodynamics biopsy of tissue and blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Premedication during the week of treatment
Study: NCT03137277

Intervention type: PROCEDURE
Intervention: screening colonoscopy
Description: Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps \< 5 mm), or conventional polypectomy according to local standards.

Intervention type: PROCEDURE
Intervention: screening colonoscopy
Description: Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps \< 5 mm), or conventional polypectomy according to local standards.
Study: NCT01753713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02543047

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioshield
Description: Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioshield
Description: Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
Study: NCT04215562

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: rehabilitation
Description: electro-therapy, heat therapy, massage and exercise therapy
Study: NCT02048124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25g standard needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25d ProCor needle
Study: NCT03984344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation
Description: The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
Study: NCT03810157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching system
Description: The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
Study: NCT01468454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18 F-DOPA
Description: 1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
Study: NCT02438280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent, Vibrational Device
Description: 20 minutes of vibration each day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcceleDent, Vibrational Device
Description: 20 minutes of vibration each day
Study: NCT02620787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tedizolid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis Catheter Insertion
Description: A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Catheter Insertion
Description: A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
Study: NCT01005069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS-32
Description: DLBS-32 100 mg once daily and lifestyle modification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS-32
Description: DLBS-32 200 mg once daily and lifestyle modification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS-32
Description: DLBS-32 300 mg once daily and lifestyle modification

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules once daily and lifestyle modification
Study: NCT04213391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sulforaphane
Description: Sulforaphane take 2550mg once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo take 2550mg once a day.
Study: NCT00710255

Intervention type: PROCEDURE
Intervention: Hyperpnea challenge
Description: 5 minutes of dry air hyperpnea to induce bronchospasm
Study: NCT05459909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Description: Daily supplementation of synbiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Description: Daily supplementation of synbiotic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Increased fruits and vegetables consumption

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Increased fruits and vegetables consumption
Study: NCT03353324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of bevacizumab
Description: under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of bevacizumab+ targeted laser
Description: patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared